RAN-CARVEDILOL TABLET
国家: 加拿大
语言: 英文
来源: Health Canada
产品特点
(SPC)
06-10-2016
该产品的某些文档当前不可用，您可以向我们的客户服务发送请求，我们将在获得它们后尽快通知您。
发送请求。
发送请求。
有效成分:
CARVEDILOL
可用日期:
RANBAXY PHARMACEUTICALS CANADA INC.
ATC代码:
C07AG02
INN（国际名称）:
CARVEDILOL
剂量:
25MG
药物剂型:
TABLET
组成:
CARVEDILOL 25MG
给药途径:
ORAL
每包单位数:
100
处方类型:
Prescription
治疗领域:
BETA-ADRENERGIC BLOCKING AGENTS
產品總結:
Active ingredient group (AIG) number: 0122683001; AHFS:
授权状态:
CANCELLED POST MARKET
授权日期:
2022-09-16
产品特点
PRODUCT MONOGRAPH
PR
RAN™-CARVEDILOL
Carvedilol Tablets, House Standard
3.125, 6.25, 12.5 and 25 mg
CONGESTIVE HEART FAILURE AGENT
Ranbaxy Pharmaceuticals Canada Inc. DATE OF REVISION:
126 East Drive SEPTEMBER 14, 2016
Brampton, Ontario
L4W 0A5
Submission Control No: 197425
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_ _
_RAN-CARVEDILOL Product Monograph _
_ _
_Page 2 of 38 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
.............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................15
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
..............................................23
PART II: SCIENTIFIC INFORMATION
...............................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
CLINICAL TRIALS
.............................................................................................
阅读完整的文件
